COMPLETEDNA

Feasibility and Performance Evaluation for INVSENSOR00024

Feasibility and Performance Evaluation of INVSENSOR00024

NCT03570255•Masimo Corporation

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Evaluation of SpO2 Performance

Interventions

RD SET Neo SpO2

Locations

1

United States

Locations (1)

Stanford University Medical Center

Stanford, California, United States

Key Dates

Start Date

June 25, 2018

Primary Completion Date

November 8, 2019

Completion Date

November 8, 2019

Last Updated

February 20, 2020

Sponsors

Lead Sponsor

Masimo Corporation

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 20, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions